Silexion Therapeutics Ltd.SLXNNASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank37
Year-over-Year Change
Year-over-year SG&A expense growth
Percentile
P37
Within normal range
vs 3Y Ago
-0.2x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q3 2025 | -10.45% |
| Q2 2025 | 19.60% |
| Q1 2025 | 8359.50% |
| Q4 2024 | -99.74% |
| Q3 2024 | 683.82% |
| Q2 2024 | 117.79% |
| Q1 2024 | -39.57% |
| Q4 2023 | 150.00% |
| Q3 2023 | 19.64% |
| Q2 2023 | 122318.90% |
| Q1 2023 | -99.97% |
| Q4 2022 | 105.95% |
| Q3 2022 | 50.96% |
| Q2 2022 | -55.17% |
| Q1 2022 | -19.19% |
| Q4 2021 | 0.00% |
| Q3 2021 | -100.00% |
| Q2 2021 | 110.53% |
| Q1 2021 | -52.69% |
| Q4 2020 | 0.00% |